We are live on ! Find out more
MCRB icon

Seres Therapeutics

152 hedge funds and large institutions have $1.85B invested in Seres Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 45 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

606% more call options, than puts

Call options by funds: $35.3M | Put options by funds: $5.01M

36% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 45

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0.17% more ownership

Funds ownership: 4.74%4.92% (+0.17%)

0% more funds holding

Funds holding: 152152 (0)

12% less capital invested

Capital invested by funds: $2.12B → $1.85B (-$264M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
152
Holders Change
Holders Change %
0%
% of All Funds
2.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
61
Reduced
45
Closed
23
Calls
$35.3M
Puts
$5.01M
Net Calls
+$30.3M
Net Calls Change
+$19.4M
Name Holding Trade Value Shares
Change
Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$302M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$253M +$21.7M +47,205 +8%
AIM
3
ARK Investment Management
Florida
$244M -$43.4M -94,266 -14%
BlackRock
4
BlackRock
New York
$127M -$2.91M -6,326 -2%
NAMA
5
Nikko Asset Management Americas
New York
$124M +$4.05M +8,788 +3%
Sumitomo Mitsui Trust Group
6
Sumitomo Mitsui Trust Group
Japan
$123M +$2.91M +6,326 +2%
RCM
7
RA Capital Management
Massachusetts
$76.1M +$85.1M +184,710 New
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$75.1M +$23.1M +50,133 +38%
Vanguard Group
9
Vanguard Group
Pennsylvania
$70.4M +$5.8M +12,598 +8%
State Street
10
State Street
Massachusetts
$69.4M -$5.78M -12,563 -7%
Federated Hermes
11
Federated Hermes
Pennsylvania
$56.9M -$4.38M -9,509 -6%
GGHC
12
Gilder Gagnon Howe & Co
New York
$53.7M -$13.3M -28,791 -18%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$29.2M -$10.7M -23,296 -25%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$20.1M +$20M +43,462 +824%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$20M +$2M +4,350 +10%
Goldman Sachs
16
Goldman Sachs
New York
$18.7M +$3.79M +8,225 +22%
Lord, Abbett & Co
17
Lord, Abbett & Co
New Jersey
$14.4M -$14.5M -31,393 -47%
Northern Trust
18
Northern Trust
Illinois
$13.2M -$984K -2,136 -6%
OM
19
Opaleye Management
Massachusetts
$9.8M -$813K -1,766 -11%
Charles Schwab
20
Charles Schwab
California
$7.87M +$232K +504 +3%
Morgan Stanley
21
Morgan Stanley
New York
$7.28M +$4.67M +10,133 +134%
FFM
22
Fairmount Funds Management
Pennsylvania
$7.27M +$2.21M +4,800 +37%
IC
23
Ikarian Capital
Texas
$7.21M +$8.06M +17,500 New
Citadel Advisors
24
Citadel Advisors
Florida
$7M +$1.17M +2,531 +17%
Millennium Management
25
Millennium Management
New York
$5.5M -$1.14M -2,481 -16%

MCRB Hedge Fund Activity: Q1 2021 in Review

152 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2021, worth a combined $1.85B — down 12% from $2.12B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MCRB positions and 23 closed out — a net gain of 2 holders — while 61 added to existing stakes and 45 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $85.1M. The largest seller was ARK Investment Management, cutting an estimated $43.4M.

  • 152 institutional investors held Seres Therapeutics (MCRB) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $1.85B of Seres Therapeutics stock for Q1 2021, down 12% quarter-over-quarter.
  • 25 funds opened new Seres Therapeutics positions in Q1 2021 and 23 closed out, a net change of +2 holders.
  • The largest Seres Therapeutics buyer in Q1 2021 was RA Capital Management, an estimated $85.1M added.
  • The largest Seres Therapeutics seller in Q1 2021 was ARK Investment Management, an estimated $43.4M sold.

Based on aggregated 13F filings for Q1 2021.